Posted On: 06/11/2015 7:50:45 PM
Post# of 63828
$OCLS financials Pr. $1.73
Total revenue increased 37% to $4 million from $2.9 million in the same period last year; up 25% from the quarter ending December 31, 2014
Cash as of March 31, 2015 of $6.1 million and debt free
Upon completion of Ruthigen merger, Oculus will receive an additional $4.5 million from the sale of Ruthigen shares
Company strategy to expand footprint in U.S. dermatology is on track: sales in the fourth quarter grew to $412,000, up $302,000 from the same period last year
Website
Shares Outstanding: 15.04M
Float: 14.88M
% Held by Insiders: 8.15%
% Held by Institutions: 10.70%
Shares Short (as of May 29, 2015): 264.30K
Short Ratio (as of May 29, 2015): 1.20
Short % of Float (as of May 29, 2015): 3.10%
Shares Short (prior month): 268.52K
Headlines
Total revenue increased 37% to $4 million from $2.9 million in the same period last year; up 25% from the quarter ending December 31, 2014
Cash as of March 31, 2015 of $6.1 million and debt free
Upon completion of Ruthigen merger, Oculus will receive an additional $4.5 million from the sale of Ruthigen shares
Company strategy to expand footprint in U.S. dermatology is on track: sales in the fourth quarter grew to $412,000, up $302,000 from the same period last year
Website
Shares Outstanding: 15.04M
Float: 14.88M
% Held by Insiders: 8.15%
% Held by Institutions: 10.70%
Shares Short (as of May 29, 2015): 264.30K
Short Ratio (as of May 29, 2015): 1.20
Short % of Float (as of May 29, 2015): 3.10%
Shares Short (prior month): 268.52K
Headlines
(0)
(0)
